Personalis (NASDAQ:PSNL) Price Target Cut to $8.00 by Analysts at HC Wainwright

Personalis (NASDAQ:PSNL) had its price objective decreased by analysts at HC Wainwright from $11.00 to $8.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 47.06% from the stock’s current price. HC Wainwright also issued estimates for Personalis’ FY2029 earnings at $0.35 EPS.

A number of other equities analysts have also commented on PSNL. Lake Street Capital increased their price target on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $7.25 target price on shares of Personalis in a report on Wednesday, January 8th.

Personalis Stock Performance

PSNL stock opened at $5.44 on Monday. The company’s fifty day moving average price is $4.90 and its 200-day moving average price is $4.75. Personalis has a one year low of $1.12 and a one year high of $7.20. The company has a market capitalization of $384.34 million, a PE ratio of -3.24 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The company had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. During the same quarter in the previous year, the firm earned ($0.51) EPS. On average, research analysts predict that Personalis will post -1.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in shares of Personalis in the 3rd quarter worth approximately $40,000. SG Americas Securities LLC bought a new stake in Personalis in the fourth quarter worth $63,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after buying an additional 4,504 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Personalis during the fourth quarter valued at $87,000. Finally, International Assets Investment Management LLC raised its stake in shares of Personalis by 438.0% in the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after acquiring an additional 17,082 shares during the period. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.